CTY

NASD City Therapeutics, Inc.
Oct 19, 2026 · 6:10 AM ET LAST TRADE Market Closed

$21.11 ↓ -1.29 (-5.74%) Trading Down from the previous close of $22.40

YTD change
-5.74%
vs 20-day SMA
N/A
vs 200-day SMA
N/A

Price ranges

Previous day
$20.50 $23.88
open $23.00 close $22.40
-$0.60 (-2.61%)
Today
$0.00 $0.00
$21.11
Past week
$0.00 $22.40
from $22.40 now $21.11
-$1.29 (-5.74%)
Past month
$0.00 $22.40
from $22.40 now $21.11
-$1.29 (-5.74%)
This year
$20.50 $23.88
from $22.40 now $21.11
-$1.29 (-5.74%)

Price & Performance

+0.00 (+0.00%) / 6M

No chart data available

Signals & Sentiment

Momentum, market sentiment, and recent alerts

N/A
  • The stock is 11.6% away from all-time highs of $23.88
  • CTY is down 6% since the beginning of the year
  • CTY is down 6% over the past 12 months
  • CTY is down 6% over the past 1 month

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable N/A
EPS N/A
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $1.2B

Balance sheet & scale

IncomeN/A
Revenue$13.6M
Cash$112.8M
Debt$211.8K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Market cap $1.1B

City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease. The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.

Competitor comparison

No peer group available for this symbol.

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.